Evaluation of the efficacy and safety of nintedanib in elderly patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. - Amsterdam 2025

Therapeutic strategies in interstitial lung disease

Chair(s): Peter Saunders, Ewa Miadlikowska

Session type: Poster session

Evaluation of the efficacy and safety of nintedanib in elderly patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.

Paolo Cameli

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Combined nintedanib and anticoagulation therapy does not increase the risk of bleeding in individuals with pulmonary fibrosis. A real world retrospective study.

Martin G. Kelly

Poster

Abstract

First-in-Human Phase I Trial: the Safety, Tolerability, and Pharmacokinetics of HSK44459 in Healthy Subjects

Juan Li

Poster

Abstract

Fostering Adherence in Ramadan for Antifibrotic Medications (FAST-AIM) - A multicentre cross-sectional study

Anna Murphy

Poster

Abstract

Antifibrotic treatment in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF):similarities and differences

Demet Polat Yulug

Poster

Abstract

Antisence Oligonucleotide Silencing of Fused in Sarcoma (FUS): A Novel Therapeutic Intervention for Idiopathic Pulmonary Fibrosis

Bhavika Katariya

Abstract

Safety and clinical impact of the concomitant use of antifibrotic drugs and anticoagulants: a single-centre retrospective study.

Alessandra Pagano

Abstract

Blood eosinophilia: possible biomarker of response to Nintedanib in Idiopathic Pulmonary Fibrosis.

Lucia Vietri

Poster

Abstract

Heterogeneous prognosis of individuals with desquamative interstitial pneumonia

Quentin Philippot

Poster

Abstract

Intravenous immunoglobulin in acute exacerbations of fibrotic interstitial lung diseases: A retrospective, real-world study

Panagiota Tsiri

Poster

Abstract

Evaluation of the efficacy and safety of nintedanib in elderly patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.

Paolo Cameli

Poster

Abstract

Gefapixant for Refractory Cough in Interstitial Lung Disease

Atsushi Saito

Poster

Abstract

High risk of myelodysplastic syndrome in patients with pulmonary fibrosis and a rare telomere related gene variant

Joanne Van Der Vis

Poster

Abstract

Nintedanib combined with pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF): a retrospective multicentre study (Combi-PF)

Elisa Martinez Besteiro

Poster

Abstract

Impact of antifibrotic treatment on clinical outcomes in idiopathic pulmonary fibrosis patients: a real-world cohort study

Maria Cristina Penaloza Ramos

Poster

Abstract

Effectiveness of Nintedanib in progressive pulmonary fibrosis assessed by progression criteria. An Italian, observational, multicentre study.

Jacopo Cefalo

Poster

Abstract

Effects of nerandomilast on pharmacokinetics of nintedanib and pirfenidone

Yichao Yu

Poster

Abstract

Antifibrotic Drug Tolerance and Treatment Management of IPF Patients: Data from 8 Centers in the Aegean Region

Muzaffer Onur Turan

Poster

Abstract

Effectiveness of nintedanib in patients with IPF who develop severe gas exchange impairment: a real-world study

Chiara Gollinucci

Poster

Abstract

ACE inhibitor use and mortality in idiopathic pulmonary fibrosis: A retrospective cohort study

Burcu Ozaltin

Poster

Abstract

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}